Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nab-paclitaxel + Gemcitabine in Advanced Pancreatic Cancer with Hyperbilirubinemia
NCT02267707Phase 1Terminated
- Sponsor
- Celgene Corporation
- Start
- May 2015
- Primary completion
- Feb 2016
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of nab-paclitaxel in pancreatic adenocarcinoma (PDAC) (2 cohorts), sponsored by Celgene Corporation. Primary endpoints: Maximum Tolerated Dose up to 20 months, Maximum Plasma Concentration and 4 more. Started May 2015; status: terminated.
02
Drugs
nab-paclitaxel
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT02267707.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02267707.